Summary
Merck & Co., Inc. (MRK) has filed an 8-K report to inform investors about a temporary trading suspension, or 'blackout period,' affecting its U.S. employee benefit plans. This blackout is directly related to the planned separation of Organon & Co. from Merck. During this period, participants in the Merck U.S. Savings Plan, MSD Employee Stock Purchase and Savings Plan, and MSD Puerto Rico Savings & Security Plan will be unable to make changes to their investments, obtain loans, or process distributions specifically concerning Merck common stock held within the plans. The blackout period is scheduled to commence on June 2, 2021, and is expected to conclude during the week of June 7, 2021. Additionally, Merck has notified its directors and executive officers of similar trading restrictions applicable to them, in accordance with Sarbanes-Oxley Act regulations. While the primary focus is on employee plans, this filing serves as a crucial disclosure for investors regarding potential operational impacts and regulatory compliance during the upcoming spin-off.
Key Highlights
- 1Temporary trading suspension (blackout period) announced for Merck's U.S. 401(k) plans.
- 2The blackout is linked to the planned separation of Organon & Co. from Merck.
- 3Participants will be restricted from directing investments, obtaining loans, or making distributions of Merck common stock within the plans.
- 4Blackout period is set to begin on June 2, 2021, and last through the week of June 7, 2021.
- 5Directors and executive officers are also subject to stock trading restrictions during this period.
- 6These restrictions are in compliance with Sarbanes-Oxley Act and related regulations.
- 7Investors can contact Merck's Corporate Secretary for specific blackout period dates.